Coherus Shrugs Off Missing Ranibizumab Pre-Filled Syringe – For Now

Launch Of Dominant Ranibizumab Presentation Planned But Timeline Uncertain

 
• By Dean Rudge

Coherus BioSciences had much to say during its second-quarter earnings call in the wake of USFDA approval for its Bioeq-partnered Cimerli biosimilar to Roche’s Lucentis.

Iurii Kirsanov/Alamy Stock Photo
Coherus is well positioned to leap on the ranibizumab opportunity • Source: Shutterstock (Iurii Kirsanov / Alamy Stock Pho/Alamy Stock Photo)

More from Biosimilars

More from Products